stockrowImmuneering Corporation
IMRXImmuneering Corporation’s revenue for fiscal 2022 (year ended December 2022) was $317,000.00.
- EPS
- +1.61%
- Free cash flow
- −40.2%
Quarter to September 2026, against a year earlier
Follow IMRX
Alert me
Immuneering Corporation (IMRX) Return on invested capital
Immuneering Corporation's return on invested capital over the twelve months to 30 September 2026 was −198.4%, down 117.1 percentage points from fiscal 2025 (−81.3%). Over the past ten years it has ranged from −764.0% (fiscal 2024) to 0.00% (fiscal 2020); the current reading is higher than 71% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −81.3% | 682.70 |
| FY2024 | −764.0% | (20.52) |
| FY2023 | −743.5% | 4.22 |
| FY2022 | −747.7% | (435.35) |
| FY2021 | −312.3% | (312.34) |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| KRRO Korro Bio, Inc. compare | 0.00% |
| ABEO Abeona Therapeutics Inc. compare | 0.00% |
| CABA Cabaletta Bio, Inc. compare | 0.00% |
| FATE Fate Therapeutics, Inc. compare | 0.00% |
| GLSI Greenwich LifeSciences, Inc. compare | 0.00% |
| ACIU AC Immune compare | 0.00% |
| VNDA Vanda Pharmaceuticals Inc. compare | −180.2% |
| IMRX Immuneering Corporation | −198.4% |
| SLGL Sol-Gel Technologies Ltd. compare | −6,630.2% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)